6.57
-0.33 (-4.78%)
| Previous Close | 6.90 |
| Open | 7.00 |
| Volume | 1,212,799 |
| Avg. Volume (3M) | 1,468,417 |
| Market Cap | 1,065,148,160 |
| Price / Sales | 9.64 |
| Price / Book | 6.19 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Profit Margin | -107.04% |
| Operating Margin (TTM) | -542.82% |
| Diluted EPS (TTM) | -0.710 |
| Quarterly Revenue Growth (YOY) | -26.80% |
| Total Debt/Equity (MRQ) | 13.13% |
| Current Ratio (MRQ) | 2.95 |
| Operating Cash Flow (TTM) | -180.63 M |
| Levered Free Cash Flow (TTM) | -133.93 M |
| Return on Assets (TTM) | -30.02% |
| Return on Equity (TTM) | -105.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Wave Life Sciences Ltd. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | -0.40 |
|
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 16.33% |
| % Held by Institutions | 85.20% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 18.00 (Wedbush, 173.97%) | Buy |
| Median | 14.00 (113.09%) | |
| Low | 10.00 (Cantor Fitzgerald, 52.21%) | Buy |
| Average | 14.00 (113.09%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 7.03 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 23 Jun 2025 | 18.00 (173.97%) | Buy | 6.57 |
| Raymond James | 11 Jun 2025 | 14.00 (113.09%) | Buy | 7.19 |
| Cantor Fitzgerald | 29 Apr 2025 | 10.00 (52.21%) | Buy | 7.34 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 20 Jun 2025 | Announcement | Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions |
| 29 May 2025 | Announcement | Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference |
| 28 May 2025 | Announcement | Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer |
| 08 May 2025 | Announcement | Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update |
| 01 May 2025 | Announcement | Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |